FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Report a Drug Shortage | FAQ | Background Info | Get Email Alerts | Download Current Drug Shortages | Contact Us

Start Over | Back to Search Results

Tirzepatide Injection
Status: Resolved
»Duration of Shortage: 12/15/2022 - 12/19/2024
»Therapeutic Categories: Endocrinology/Metabolism

Expand all

Eli Lilly and Co. (Revised 12/19/2024)

Company Contact Information:
800-545-5979

Presentation

• Mounjaro, Injection, 5 mg/.5 mL (NDC 0002-1495-80)
• Mounjaro, Injection, 10 mg/.5 mL (NDC 0002-1471-80)
• Mounjaro, Injection, 2.5 mg/.5 mL (NDC 0002-1506-80)
• Mounjaro, Injection, 7.5 mg/.5 mL (NDC 0002-1484-80)
• Mounjaro, Injection, 12.5 mg/.5 mL (NDC 0002-1460-80)
• Mounjaro, Injection, 15 mg/.5 mL (NDC 0002-1457-80)
• Zepbound, Injection, 5 mg/.5 mL (NDC 0002-2495-80)
• Zepbound, Injection, 12.5 mg/.5 mL (NDC 0002-2460-80)
• Zepbound, Injection, 2.5 mg/.5 mL (NDC 0002-2506-80)
• Zepbound, Injection, 7.5 mg/.5 mL (NDC 0002-2484-80)
• Zepbound, Injection, 10 mg/.5 mL (NDC 0002-2471-80)
• Zepbound, Injection, 15 mg/.5 mL (NDC 0002-2457-80)

Note:

• Even when a medication is available, patients may not always be able to immediately fill their prescription at a particular pharmacy. That is especially true for refrigerated products and products with multiple dose strengths, due to factors like ordering practices and incentives, cold chain logistical considerations, and retailer capacity constraints. Patients may experience variability at a particular pharmacy location regardless of whether a drug is in shortage.